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Introduction
Chronic Neutropenias (CNP) represent a wide spectrum of
disorders ranging from mild to life-threatening, congenital or
acquired diseases characterized by absolute neutrophil counts
below 1.5109 /L for at least 3 months.1
Congenital Neutropenias comprise rare disorders of neutrophil
production associated with mutations in more than 20 recognized
genes but also with still unknown genetic aberrations, resulting in
impaired neutrophil differentiation and/or survival, varying degree
of propensity toMyelodysplastic Syndrome (MDS)/AcuteMyeloid
Leukemia (AML) and frequent dysfunction of non-hemopoietic
organs.2–6 Unfolded protein responses, endoplasmic reticulum
stress, elevated apoptosis, deregulated expression of transcription
factors, abnormalities in secretory vesicles and mitochondrial
metabolism, aberrations in ribosomebiogenesis andassemblyhave
been recognized as possible pathogeneticmechanisms.2–5 Congen-
ital Neutropenias also include benign familial or ethnic variations
associatedwith polymorphisms of knownor yet unidentified genes
with unknown frequency and pathophysiologic significance that
need further investigation.7,8 Acquired CNP encompass diverse
disease entities mediated through neutrophil-directed antibodies,
cellular (NK- or T-cell) or cytokine dependent immune processes
or via unknown pathogenetic mechanisms.9–12 These latter
categories, also known as idiopathic CNP, include benign and
uncomplicated forms of the disease but also pre-MDS cases,
associated or not with clonal hemopoiesis, that need early
recognition and close monitoring.9–12
The treatment of patients with CNP depends on the type and
severity of the underlying disease. The management ranges from
simple follow-up of uncomplicated cases, to systemic adminis-
tration of granulocyte colony stimulating factor (G-CSF),
antibiotics and immunomodulatory agents, to more drastic
therapies with the potential to cure, that is, hemopoietic stem cell
(HSC) transplantation or even to experimental gene-based
interventions using CRISPR-Cas9 technology.1,13–16
The challenges in CNP and the importance of
networking
The diagnosis of congenital and acquired CNP remains a
challenge with the underlying mechanisms still obscure in 30% to
50% of patients. Moreover, the variability in genotypic/
phenotypic characteristics and natural history of these patients
has thus far precluded defining common treatment patterns and
guidance whereas the rarity of the underlying diseases has
resulted in difficulties in recruiting patients for clinical trials. The
collaboration between clinicians and scientists with special
interest in these diseases as well as the establishment and
interconnection of CNP patient Registries and Biobanks are
essential prerequisites for the generation of a rich source of real-
world data that will both facilitate the accurate diagnosis
and contribute to a consensus on patient management; foster
research on the pathogenetic/pathophysiologic mechanisms; and,
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give more opportunities for the development of novel and
personalized treatment approaches as well as initiation of clinical
trials.
A wide European network for the diagnosis and treatment of
CNP (EuNet-INNOCHRON; https://www.eunet-innochron.
eu/) funded by the European Cooperation of Science and
Technology (COST) was launched in November 2019 (Fig. 1).
It consists of clinicians and scientists from diverse scientific
areas, early career investigators and biotechnological enter-
prises from more than 30 countries, mostly European, while
also involving as collaborating partners the Severe Chronic
Neutropenia International Registry (SCNIR; https://severe-
chronic-neutropenia.org) and the European Hematology
Association (EHA). EuNet-INNOCHRON is open to any
clinician, researcher, scientific or patient society with a special
focus in CNP. The network aims to: (a) harmonize the
laboratory investigation of different types of CNP by facilitat-
ing the exchange of knowledge, tools, reagents, protocols and
experience through inter-institutional collaborations; (b)
formulate common diagnostic algorithms and treatment guide-
lines for patients with different types of CNPs aligned with the
concepts of precision medicine; (c) organize new and expand
existing CNP patient Registries and Biobanks using common
protocols for sample collection, storage and management as
well as template forms for patients’ informed consent according
to the ethical standards of the European Legal Framework and
the national and local regulations; (d) collect real-world data on
the epidemiology, clinical presentation and natural course of
CNPs and identify markers for improved decision-making and
risk-adapted treatment strategies; (e) promote training and
education of young investigators on advanced techniques; (f)
foster entrepreneurial innovation and explore novel approaches
for targeted drug development and innovative clinical trial
design in collaboration with industrial partners. EuNet-
INNOCHRON has adopted an excellence and inclusiveness
policy and gives particular interest in the involvement of young
researchers by offering a number of networking tools such as
scientific meetings, short term scientific mission exchanges,
training schools and conference grants.
Perspectives for scientific innovations within
EuNet-INNOCHRON
Five distinct but complementary Working Groups (WG) have
been carefully designed within EuNet-INNOCHRON to address
the challenges in CNP and promote breakthrough scientific
developments and new concepts in the diagnosis, management
and treatment of these patients (Table 1).
Congenital neutropenias
This WG will perform whole exome sequencing (WES) studies
in patients with unknownmutations and healthy family members
and promote collaborations in this field; candidate genes will be
functionally interrogated for their role in granulocyte differenti-
ation by generating induced pluripotent stem (iPS) cell lines from
patients. Abnormal genes will be corrected in patient-derived iPS
cells using CRISPR-Cas9 technology and the potential improve-
ment of in vitro granulocytic differentiation of the gene corrected
iPS cell lines will be evaluated. Candidate gene mutations will be
Figure 1. A schematic representation of the EuNet-INNOCHRON Action. The figure depicts the main WG of the Action with the respective Tasks as well as
the tools for addressing the challenges in the field of CNP. The main networking tools to achieve the objectives of the Action are also shown. CNP = chronic
neutropenia, ECI = early career investigators, EHA-SWG = European Hematology Association – Scientific Working Groups, NGS = next generation sequencing,
STSM = short term scientific missions, TS = training schools, WES = whole exome sequencing, WG = working group.
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Table 1
Challenges in CNP and perspectives through EuNet-INNOCHRON
Challenges Perspectives through EuNet-INNOCHRON
1. Congenital Neutropenias
The genetic defect(s) underlying these diseases is obscure in
a significant proportion of patients.
The pathophysiologic mechanisms leading to neutropenia are
unclear even in cases with well-defined molecular defects.
Limited availability of primary patient cells.
The MDS/AML evolution in patients with specific disease types
is a process with still unknown pathogenesis; predictive
biomarkers are not available.
Curative therapies are not available, excluding HSC
transplantation. The field is open for:
Personalized treatment approaches.
Identification of targets for novel therapies.
The rarity of the diseases results in difficulties in designing
clinical trials.
WES studies will be performed in patients with unknown mutations and healthy family members.
Exchange of knowledge and results between the different laboratories will be initiated.
Studies with iPS cells:
- iPS cell lines from selected patients will be generated and candidate genes will be corrected using
CRISPR-Cas9 technology.
- Candidate gene mutations will be introduced in iPS cells from healthy individuals to study the
defective intracellular signaling pathways.
CRISPR/Cas9 will be used to generate Zebrafish deficient for candidate genes or transgenic fish
carrying patient-specific gene mutations.
Novel methods will be developed to measure translation rates and analyze structures of native ribosome
assembly intermediates from patient cells.
Large-scale and longitudinal NGS studies will be performed in patients prone to develop MDS/AML.
iPS cell-based and genome editing technologies will be used to elucidate the role of stress
mechanisms, interrogate the sequential events leading to MDS/AML and develop strategies to
redirect premalignant progenitors.
New therapeutic strategies will be designed based on the iPS, genome editing and Zebrafish findings.
The effect of molecules interfering with pathways of granulopoiesis will be evaluated in iPS cell lines
from patients and Zebrafish and xenograft mouse models as well as in primary HSCs.
The Network has already and is also open to industrial partners who are expected to facilitate the
development of clinical trials.
2. Acquired CNP
Autoantibody-mediated
Detection of anti-neutrophil autoantibodies through high
sensitivity and specificity techniques is not widely available
and needs Reference Laboratories.
Rare diseases underlying anti-neutrophil antibody production,
such as PID and ALPS, need to be excluded.
Experts from Reference Laboratories in anti-neutrophil antibodies detection have key roles in the
Network and will contribute to:
Exchange and transfer of knowledge on the different kinds of anti-neutrophil antibodies, their
diagnostic value, and high-quality detection techniques;
Training activities i.e. STSMs and TS.
Partners within the Network have the potential for clinical and laboratory integrated comprehensive
approach of PID and ALPS including NGS or WES and will offer diagnostic and training opportunities.
Non-antibody mediated
Idiopathic CNP is an heterogenous disorder with multiple and
poorly defined pathogenetic mechanisms; diagnosis is
based on exclusion criteria.
Diagnostic algorithms are not widely available.
The role of cell-mediated mechanisms needs further
evaluation.
Cases with benign course should be distinguished from
CNP cases preceding MDS.
Researchers within the Network will:
Develop diagnostic algorithms to ensure the diagnosis of Idiopathic CNP;
Probe the TCR gene repertoires from different idiopathic CNP patients to identify disease-specific
clonotypes;
Investigate the role of MDSCs;
Study the interactions between BM granulocytic progenitors and MSCs.
Develop NGS panels and WES for the recognition of CNP-associated mutations or SNPs as well as
clonal hemopoiesis and will longitudinally monitor patient clones in relation to patient outcome.
3. Patient Registries and Biobanking
Few Registries and Biobanks for CNP patients exist in Europe.
More than 30% of patients remain undiagnosed due to non-
accessibility to advanced techniques.
Absence of real-world data from large number of patients with
different types of CNP.
The rarity of different types of CNP results in difficulties in
recruiting patients for clinical trials.
Unified protocols for patient registration and biobanking are
needed under the ethics and standards of the European
Legal Framework.
Absence of a reliable classification for CNP in the ICD system
Experts representing well established international (SCNIR) and national CNP patient Registries have key
roles in the Network; they will provide expertise for the establishment of new and interconnection of
the existing Registries.
A WG within the Network will propose guidelines for biobanking.
Real-world data will be collected and reliable statistics will be obtained on incidence, prevalence,
morbidity, mortality, infections’ rate, QoL, proportion of patients receiving G-CSF and dose, number of
patients undergoing HSC transplantation, comorbidities and rate of MDS/AML.
Patient samples will be collected systematically within the Network for diagnostic and research
purposes.
Opportunities for clinical trials will emerge.
A single classification of all different diseases associated with CNP will be proposed.
4. Overarching challenge
CNP includes a wide variety of heterogeneous diseases for
which no comprehensive diagnostic and treatment
indications are currently available.
Often diagnostic and treatment needs differ in children and
adults.
The Network includes a large number of European and overseas experts in childhood and adult CNP.
The Action is strongly endorsed by EHA. One of the most important fields of activity of EHA is
elaboration of Guidelines. This background offers a unique opportunity to produce guidelines on CNP
based on the largest panel of experts worldwide.
ALPS = autoimmune lymphoproliferative syndrome, AML = acute myeloid leukemia, BM = bone marrow, CNP = chronic neutropenia, EHA = European Hematology Association, G-CSF = granulocyte colony
stimulating factor, HSC = hemopoietic stem cells, ICD = International Classification of Diseases, iPS cells = induced pluripotent stem cells, MDS = myelodysplastic syndrome, MDSC = myeloid derived
suppressor cells, MSC=mesenchymal stem cells, NGS= next generation sequencing; PID= primary immune deficiencies, QoL= quality of life, SCNIR= severe chronic neutropenia international registry, SNP=
single nucleotide polymorphism, STSM = short term scientific missions, TS = training schools, WES = whole exome sequencing.
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also introduced into iPS cells derived from healthy individuals
and their effects on granulocyte differentiation will be evaluated
in vitro.14,17 RNA-sequencing analysis of HSCs generated from
isogenic iPS cell lines will help to identify deregulated intracellular
signaling pathways and candidate factors underlying the cellular
phenotypes of neutropenias. CRISPR-Cas9 will be used to
generate Zebrafish either deficient for the candidate genes or
carrying patient-specific gene mutations. This WGwill also study
the CNP associated with Shwachman-Diamond Syndrome (SDS)
to better understand the role of the causative genes SBDS, EFL1,
andDNAJC21 in ribosome assembly and also provide templates
for the development of novel therapeutics.18 Robust, viable
animal models will be generated and exploited to better
understand SDS pathogenesis and promote the development of
new therapeutics. A key objective of this WG is to establish new
collaborations to achieve our goals.
Acquired CNP
ThisWGwill invest in collaborativework for the investigationof
antibody- and non-antibody mediated CNP. An important goal is
to raise awareness of the diversity of acquireCNP and the available
diagnostic platforms. Emphasis will be given on the transfer of
knowledge and methodological hands-on training on the high-
quality detection of anti-neutrophil autoantibodies (sensitivity and
specificity). Many traditional techniques are present in special
laboratorieswhereas newdiagnostic platforms are availablewith a
potential formorewide-spread use.Novel diagnostic tools, such as
next generation sequencing (NGS) including WES to understand
better rare diseases that can by themselves cause antibody-
mediated CNP, such as autoimmune lymphoproliferative syn-
drome (ALPS) and primary immune deficiencies (PID), will be
performed.19 Regarding the non-antibody-mediated CNPs, par-
ticular networking will be directed to the idiopathic cases.
Specifically, the WG will help to probe the T cell receptor gene
repertoires fromdifferent patients with idiopathic CNPusingNGS
and results will be compared with public databases or databases
from other diseases with overlapping features (eg, proliferations of
T large granular lymphocytes, other bone marrow [BM] failure
syndromes) to identify disease-specific but also shared clono-
types.11 The role of myeloid cell populations, namely myeloid
derived suppressor cells (MDSC), will also be explored in
idiopathic CNP as well as the significance of clonal hemopoiesis
in correlation with patient outcome.20
Mechanisms of leukemic evolution
MDS/AML evolution in specific types of CNPs is a multistep
process of sequential hits and predictive biomarkers are not
available.21 Congenital CNP is an interesting model to study
leukemogenesis considering that the very first mutation of the
process is acting in both hemopoietic cells and the BM
microenvironment since embryogenesis. Large-scale application
ofNGS in these cases as well as in acquired CNPwith a propensity
to develop MDS/AML will significantly improve diagnosis
and risk stratification. LongitudinalNGS studieswill be performed
to provide new insights into driver mutations and stepwise
transformation. This WG will also investigate the role of cellular
stressmechanisms in leukemic evolution.Novel tools, based on iPS
cells and genome editing technologies will be developed to
elucidate these stress mechanisms and interrogate the sequential
events leading to MDS/AML. Key findings will be exploited to
develop strategies to redirect premalignant progenitors back to
normal. The WG will also establish ultra-deep sequencing of the
critical region of the CSF3R and RUNX1 genes and will also
explore the importance of these acquired mutations in leukemic
evolution through longitudinal retrospective analysis of multiple
BM samples of large number of patients with Congenital
Neutropenias. Animal models (Mice and Zebrafish) will be also
used to study molecular mechanisms of leukemogenesis triggered
by CSF3R and RUNX1 mutations. The landscape and clonal
dynamics of genome-wide somatic mutations associated with
MDS/AMLtransformation inSDSwill be investigated in single-cell
derived HSC and progenitor cell colonies from these patients.
Identification of targets for novel therapies
It has been shown that activation of the NAMPT/NAD+/
SIRTs-mediated signaling as compensatory mechanisms of the G-
CSF-mediated granulopoiesis results in induction of granulopoi-
esis in healthy individuals and CNP patients.22 This WG will
promote studies on the evaluation of the effects of different
NAMPT and SIRT1 activators as well as the NAMPT substrate,
nicotinamide, on the G-CSF-induced granulopoiesis in vitro
using iPS cell-based hemopoietic differentiation, primary BM
HSCs, and inZebrafish andxenograftmousemodels. TheWGwill
also facilitate the establishment of iPS cell lines from Congenital
Neutropenia patients with different gene mutations and will study
the effects of small molecules on the granulocytic differentiation.
Small molecules capable of inducing differentiation will next be
tested in primary HSCs and in animal models, including Zebrafish
andMice. We will also promote research on the potential of novel
molecules to interfere with neutrophil elastase whose malfunction
is a frequent cause of Congenital Neutropenia. Inhibitors of
neutrophil elastase proteolytic activity are expected to broaden the
therapeutic opportunities for these patients.23
CNP patient Registries and biobanking
Partners from national CNP patient registries, biobanking
consortia and SCNIR will contribute to the organization and
interconnection of CNP patient Registries and Biobanks at the
European level.24 The WG will contribute to the standardization
of the modus operandi of the national CNP Registries across
participant countries to ensure reliable statistics and standard
indicators on incidence, prevalence, morbidity, mortality,
infection rates, quality of life, proportion of patients receiving
G-CSF and dose, number of patients undergoing HSC transplan-
tation, comorbidities and rate of MDS/AML. Given that the
availability of Biobanks is a prerequisite for progress in
understanding CNPs and improving patient care, the WG will
promote the systemic and standardized collection of patient
samples andwill propose guidelines for biological data collection,
management, sharing and transfer according to the European
Legal Framework taking also into account national and regional
ethical and regulatory aspects. Issues specific to the type of
samples (serum, blood and/or BM cells, others) and the time
points of collection to allow pertinent study in close linkage with
clinical data will be defined. Finally, theWGwill propose a single
classification of all different diseases associated with CNP.
Capacity building within EuNet-INNOCHRON
and beyond
The EuNet-INNOCHRON is an open network focused on the
investigation, characterization, harmonization of diagnosis and
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treatment of CNPs, promotion of research, technology and
entrepreneurial innovation, consisting so far of more than 30
countries. The Action was built on a network of experts in the
field of CNP with long-standing collaborations and further
enriched with scientists of diverse expertise to achieve an
interdisciplinary and multidisciplinary approach to study the
pathogenesis of CNP and is open to researchers, particularly at
early career stages, related scientific societies, patient organiza-
tions, biotechnology and pharmaceutical companies. A key
intention of EuNet-INNOCHRON is to foster broad collabo-
rations and open theway for cutting-edge research and transfer of
knowledge to the clinic. The consortium is anticipated to
strengthen the interactions among experts in the field of CNP at
the European level and beyond, to facilitate and extend the
collaboration between existing outstanding networks such as
EHA-Scientific Working Groups, SCNIR and national Registries
for the introduction of common policies in CNP Registries and
Biobanks, and, most importantly, to contribute to the generation
of the future leading physicians and researchers in the field of
CNPs with appropriate knowledge and skills to promote further
research, innovation and personalized patient treatment.
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